Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting

Phase 3

RYZ101 vs. SOCStudy of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Sponsor:

RayzeBio, Inc.

Code:

NCT05477576

Conditions

GEP-NET

Gastroenteropancreatic Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor Disease

Neuroendocrine Tumors

Carcinoid

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RYZ101

Everolimus

Sunitinib

Octreotide

Lanreotide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-27. This information was provided to ClinicalTrials.gov by RayzeBio, Inc. on 2025-03-25.